Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 07, 2024 13:08 ET | Source: Hagens Berman Sobol Shapiro LLP

AMLX 2-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Amylyx Pharmaceuticals (AMLX) Investors with Substantial Losses to Contact Firm Before Apr. 9th Deadline in Securities Fraud Class Action

SAN FRANCISCO, April 07, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors who suffered substantial losses to submit your losses now. Class Period:...
April 04, 2024 12:50 ET | Source: Hagens Berman Sobol Shapiro LLP

AMLX 5-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Amylyx Pharmaceuticals (AMLX) Investors with Substantial Losses to Contact Firm Before Apr. 9th Deadline in Securities Fraud Class Action

SAN FRANCISCO, April 04, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors who suffered substantial losses to submit your losses now. Class...
April 01, 2024 12:59 ET | Source: Hagens Berman Sobol Shapiro LLP

Amylyx Pharmaceuticals (AMLX) Tanks 80% After RELYVRIO® ALS Treatment Fails Phase 3, Follows Securities Class Action Complaint – Hagens Berman

SAN FRANCISCO, April 01, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors who suffered substantial losses to submit your losses now. Class Period:...
March 28, 2024 15:42 ET | Source: Hagens Berman Sobol Shapiro LLP

AMLX 12-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Amylyx Pharmaceuticals (AMLX) Investors with Substantial Losses to Contact Firm Before Apr. 9th Deadline in Securities Fraud Class Action

SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors who suffered substantial losses to submit your losses now. Class Period:...
March 25, 2024 14:33 ET | Source: Hagens Berman Sobol Shapiro LLP

Investors Sue Amylyx Pharmaceuticals (AMLX) After Analyst Questions RELYVRIO® Data – Hagens Berman

SAN FRANCISCO, March 25, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors who suffered substantial losses to submit your losses now. Class Period:...
March 22, 2024 09:21 ET | Source: Hagens Berman Sobol Shapiro LLP

Amylyx Pharmaceuticals (AMLX) Tanks 80% After RELYVRIO® ALS Treatment Fails Phase 3, Follows Securities Class Action Complaint – Hagens Berman

SAN FRANCISCO, March 22, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors who suffered substantial losses to submit your losses now. Class Period:...
March 18, 2024 13:43 ET | Source: Hagens Berman Sobol Shapiro LLP

Amylyx Pharmaceuticals (AMLX) Tanks 80% After RELYVRIO ALS Treatment Fails Phase 3, Follows Securities Class Action Complaint – Hagens Berman

SAN FRANCISCO, March 18, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors who suffered substantial losses to submit your losses now. Class Period:...
March 13, 2024 18:50 ET | Source: Hagens Berman Sobol Shapiro LLP

Amylyx Pharmaceuticals (AMLX) Tanks 80% After RELYVRIO ALS Treatment Fails Phase 3, Follows Securities Class Action Complaint – Hagens Berman

SAN FRANCISCO, March 13, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors who suffered substantial losses to submit your losses now. Class Period:...
February 26, 2024 11:39 ET | Source: Johnson Fistel, LLP

AMLX NEWS: Johnson Fistel Encourages Amylyx Investors to Seek Counsel Before the Lead Plaintiff Deadline

SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP notifies investors of Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”) (NASDAQ: AMLX) that a securities class action lawsuit...
February 22, 2024 18:57 ET | Source: Hagens Berman Sobol Shapiro LLP

Investors Sue Amylyx Pharmaceuticals (AMLX) After Analyst Questions RELYVRIO® Data – Hagens Berman

SAN FRANCISCO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors who suffered substantial losses to submit your losses now. Class...